
    
      Part A is a Dose-Escalation Study in Participants with Relapsed or Refractory Esophageal
      Cancer or Gastro-Esophageal Junction Tumors. Parts B, C, D and E are expansion cohorts of
      Patients with Relapsed or Refractory Esophageal Cancer, Gastro-Esophageal Junction Tumors and
      Gastric Adenocarcinoma.

      Part F is a Dose-Escalation and Expansion Cohorts with DKN-01 + Pembrolizumab in Patients
      with Recurrent or Metastatic Esophageal Cancer, Gastroesophageal Junction Cancer or Gastric
      Adenocarcinoma with Wnt Signaling Alterations.

      Patients who are unable to receive paclitaxel or pembrolizumab for any reason will be allowed
      to receive single agent DKN-01 as part of a monotherapy substudy.
    
  